Comprehensive Serum Glycopeptide Spectra Analysis Combined with Machine Learning for Early Detection of Lung Cancer: A Case-Control Study.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: In 199 untreated lung-cancer cases and 590 healthy controls, neural/XGBoost models combined tumor markers with 1688 serum glycopeptide features; repeated random 70/30 splits produced AUC .935. Case-control design/healthy controls can inflate screening discrimination; no prospective/external validation.
Technology: In 199 untreated lung-cancer cases and 590 healthy controls, neural/XGBoost models combined tumor markers with 1688 serum glycopeptide features; repeated random 70/30 splits produced AUC .935. Case-control design/healthy controls can inflate screening discrimination; no prospective/external validation.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- In 199 untreated lung-cancer cases and 590 healthy controls, neural/XGBoost models combined tumor markers with 1688 serum glycopeptide features; repeated random 70/30 splits produced AUC .935. Case-control design/healthy controls can inflate screening discrimination; no prospective/external validation.
- Limitation / still unknown
- In 199 untreated lung-cancer cases and 590 healthy controls, neural/XGBoost models combined tumor markers with 1688 serum glycopeptide features; repeated random 70/30 splits produced AUC .935. Case-control design/healthy controls can inflate screening discrimination; no prospective/external validation.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.mdpi.com/2072-6694/17/9/1474 · https://pubmed.ncbi.nlm.nih.gov/40361401/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.